- Home
- REGN vs PSA Comparison
REGN vs PSA Comparison
Compare REGN & PSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- PSA
- Stock Information
- Founded
- REGN 1988
- PSA 1972
- Country
- REGN United States
- PSA United States
- Employees
- REGN N/A
- PSA N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- PSA Real Estate Investment Trusts
- Sector
- REGN Health Care
- PSA Real Estate
- Exchange
- REGN Nasdaq
- PSA Nasdaq
- Market Cap
- REGN 59.9B
- PSA 51.9B
- IPO Year
- REGN 1991
- PSA N/A
- Fundamental
- Price
- REGN $558.87
- PSA $279.00
- Analyst Decision
- REGN Buy
- PSA Buy
- Analyst Count
- REGN 21
- PSA 12
- Target Price
- REGN $823.86
- PSA $339.00
- AVG Volume (30 Days)
- REGN 940.4K
- PSA 974.9K
- Earning Date
- REGN 08-01-2025
- PSA 07-30-2025
- Dividend Yield
- REGN 0.63%
- PSA 4.30%
- EPS Growth
- REGN 5.03
- PSA N/A
- EPS
- REGN 39.67
- PSA 9.17
- Revenue
- REGN $14,214,200,000.00
- PSA $4,758,111,000.00
- Revenue This Year
- REGN N/A
- PSA $1.56
- Revenue Next Year
- REGN $6.65
- PSA $3.90
- P/E Ratio
- REGN $14.09
- PSA $30.41
- Revenue Growth
- REGN 5.38
- PSA 2.13
- 52 Week Low
- REGN $476.49
- PSA $256.60
- 52 Week High
- REGN $1,211.20
- PSA $369.99
- Technical
- Relative Strength Index (RSI)
- REGN 54.16
- PSA 40.64
- Support Level
- REGN $541.61
- PSA $284.17
- Resistance Level
- REGN $563.59
- PSA $293.54
- Average True Range (ATR)
- REGN 15.37
- PSA 6.05
- MACD
- REGN -0.75
- PSA -0.64
- Stochastic Oscillator
- REGN 41.57
- PSA 34.94
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About PSA Public Storage
Public Storage is the largest owner of self-storage facilities in the US, with more than 3,300 self-storage facilities in 40 states and approximately 245 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.